Citigroup Issues Positive Forecast for GSK (LON:GSK) Stock Price

GSK (LON:GSK) had its target price boosted by Citigroup from GBX 1,900 to GBX 2,250 in a report released on Monday, Marketbeat.com reports. Citigroup currently has a buy rating on the stock.

Several other equities analysts also recently weighed in on the company. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,100 price objective on shares of GSK in a report on Wednesday, January 7th. Shore Capital Group restated a “buy” rating and issued a GBX 2,300 price objective on shares of GSK in a report on Wednesday, February 4th. Berenberg Bank increased their target price on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a report on Monday, November 24th. Finally, UBS Group reissued a “neutral” rating and issued a GBX 1,940 price target on shares of GSK in a research report on Friday, January 23rd. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of GBX 1,917.86.

GSK Stock Up 0.8%

Shares of LON GSK opened at GBX 2,198 on Monday. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The business’s 50 day moving average is GBX 1,854.10 and its two-hundred day moving average is GBX 1,676.59. GSK has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 2,066. The firm has a market cap of £88.68 billion, a price-to-earnings ratio of 16.53, a PEG ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last released its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Research analysts predict that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling

In other news, insider Jonathan Symonds acquired 2,500 shares of GSK stock in a transaction dated Thursday, February 5th. The shares were acquired at an average cost of GBX 2,114 per share, for a total transaction of £52,850. Also, insider Wendy Becker acquired 441 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were purchased at an average cost of GBX 1,809 per share, with a total value of £7,977.69. Over the last three months, insiders acquired 4,591 shares of company stock worth $9,069,269. Insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.